Global Bronchodilators Market to Grow at 4.15% During 2025-2033, Spurred by COVID-19 Pandemic

December 27, 2024 | Healthcare

According to the latest report by IMARC Group, titled “Bronchodilators Market Report by Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), Drug Type (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), Route of Administration (Oral, Injection, Inhaler), and Region 2025-2033,” the global bronchodilators market reached a value of USD 39.3 Billion in 2024. Bronchodilators refer to a class of medications used for treating asthma, chronic obstructive pulmonary disease (COPD), allergic reactions, emphysema, and other breathing problems. These respiratory agents clear the mucus from the lungs, decrease airway resistance, and relax bronchial muscles to promote optimal airflow. Depending on the use, they are differentiated into short- and long-acting bronchodilators. They can be prescribed along with inhaled steroids, such as corticosteroids, to reduce inflammation and prevent asthma flare-ups.

Global Bronchodilators Market Trends

One of the key factors driving the global bronchodilators market is the rising prevalence of respiratory disorders due to the coronavirus (COVID-19) pandemic. In line with this, the increasing geriatric population, which is more susceptible to these ailments, is further facilitating the product adoption across the globe. Additionally, the rising pollution levels and increasing consumption of tobacco-based products are also accelerating the risks of contracting pulmonary diseases, which is contributing to the market growth. Apart from this, manufacturers are consistently investing in research and development (R&D) activities to engineer novel drug administration systems and improve diagnostic modalities. They are also upgrading existing devices with advanced technologies to increase the absorption of the drug in the body, such as ultrasonic nebulizers, which is creating a positive outlook for the market. Furthermore, the launch of several educational programs regarding disease prevention by governments of various nations is fueling the market growth. The rising healthcare expenditure and the increasing shift toward non-invasive treatment options are some of the other factors catalyzing the market growth. Looking forward, IMARC Group expects the market value to reach USD 57.7 Billion by 2033, exhibiting a CAGR of 4.15% during 2025-2033.

Market Summary:

  • Based on the indication, the market is divided into asthma, chronic obstructive pulmonary disease (COPD), and others.
  • On the basis of the drug type, the market has been classified into sympathomimetics, anticholinergics, phosphodiesterase inhibitor, and combination drugs.
  • Based on the route of administration, the market is segmented into oral, injection, and inhaler.
  • Region-wise, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
  • The competitive landscape of the industry has also been examined, with some of the key players being Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc.
     

Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Indication, Drug Type, Route of Administration, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Bronchodilators Market to Grow at 4.15% During 2025-2033, Spurred by COVID-19 Pandemic
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials